Signaturefd LLC increased its position in shares of Novartis AG (NYSE:NVS - Free Report) by 7.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 43,091 shares of the company's stock after buying an additional 3,001 shares during the quarter. Signaturefd LLC's holdings in Novartis were worth $4,804,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in NVS. JPMorgan Chase & Co. increased its holdings in Novartis by 35.6% during the 4th quarter. JPMorgan Chase & Co. now owns 423,142 shares of the company's stock worth $41,176,000 after purchasing an additional 111,066 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Novartis by 5.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 165,442 shares of the company's stock valued at $16,099,000 after buying an additional 8,186 shares during the last quarter. Wealthcare Advisory Partners LLC grew its holdings in Novartis by 9.0% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,041 shares of the company's stock worth $339,000 after buying an additional 252 shares in the last quarter. Legacy Financial Advisors Inc. raised its position in Novartis by 23.8% in the 4th quarter. Legacy Financial Advisors Inc. now owns 13,721 shares of the company's stock valued at $1,335,000 after buying an additional 2,635 shares during the last quarter. Finally, Brighton Jones LLC lifted its stake in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock valued at $599,000 after acquiring an additional 2,666 shares in the last quarter. Institutional investors own 13.12% of the company's stock.
Novartis Stock Performance
NYSE:NVS traded up $0.04 on Monday, reaching $121.06. 1,593,963 shares of the company's stock were exchanged, compared to its average volume of 1,996,568. The firm has a market cap of $255.73 billion, a price-to-earnings ratio of 18.92, a P/E/G ratio of 1.64 and a beta of 0.59. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.79 and a quick ratio of 0.61. The stock has a fifty day simple moving average of $116.01 and a 200-day simple moving average of $109.91. Novartis AG has a 52 week low of $96.06 and a 52 week high of $124.83.
Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.12 by $0.16. Novartis had a net margin of 24.70% and a return on equity of 39.44%. The company had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. During the same period last year, the firm earned $1.80 EPS. Novartis's revenue for the quarter was up 11.9% on a year-over-year basis. As a group, sell-side analysts predict that Novartis AG will post 8.45 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, BNP Paribas upgraded shares of Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $123.67.
Check Out Our Latest Report on Novartis
Novartis Company Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Read More

Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.